Stem cell treatment to prevent lung disease in very premature babies
Part of Genetic & congenital, Lungs & breathing clinical trials.
This Phase 1 trial tests whether giving stem cells into a breathing tube is safe and may help prevent bronchopulmonary dysplasia (BPD), a serious lung condition in very premature infants. It focuses on babies soon after birth who already need breathing support and are at risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby is 3 to 30 days old after birth
- Baby was born very early (about 23 to 29 weeks) and is not older than 36 weeks after weeks-in-pregnancy plus weeks-after-birth
- Baby’s birth weight was between 501 g and 1249 g
- Baby has an endotracheal breathing tube in place for standard care and is not being intubated just for this study
- Baby needs breathing support and has had worse or no improvement in the ventilator settings in the last 24 hours
- Parent/guardian gives written consent and agrees to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if stem cells can help premature babies with severe lung disease (bronchopulmonary dysplasia). It is for very small, early-born babies who still need a breathing machine between 5 and 14 days after birth.
This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.
This trial tests a medicine called zelpultide alfa in very premature babies who are at high risk of developing bronchopulmonary dysplasia (BPD), a chronic lung disease. The goal is to see if it can help prevent or lessen lung problems compared to standard care alone.
This study looks at babies born very early who have severe lung disease (grade 3 BPD) and still need a breathing machine. Researchers will use tests to understand their lung problems better, which may help guide their care.
This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
Hear when a new Bronchopulmonary Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.